Treatment strategies for persistent methicillin‐resistantStaphylococcus aureusbacteraemia
Open Access
- 4 May 2018
- journal article
- review article
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 43 (5) , 614-625
Abstract
What is known and objective Treatment of methicillin‐resistant Staphylococcus aureus (MRSA) bacteraemia is a long‐standing challenge to health care, often complicated by metastatic infections, treatment failure and mortality. When MRSA bacteraemia persists despite adequate initial treatment, current Infectious Diseases Society of America guidelines recommend evaluation and removal of possible sources of infection. In addition, a change in therapy may be considered. The objective of this review was to explore the therapeutic options for the treatment of persistent MRSA bacteraemia. Methods A literature search of PubMed, MEDLINE and Google Scholar was performed using the following search terms: [methicillin‐resistant Staphylococcus aureus OR MRSA] AND [bacteraemia OR bloodstream infection] AND [persistent OR persistence OR refractory OR treatment failure OR salvage] AND treatment. We evaluated relevant, adult, English‐language, peer‐reviewed studies published between 1985 and May 2018. In vitro and animal studies were considered as supportive of in vivo data. Results and discussion Randomized, controlled trials are lacking. However, case series and case reports support multiple treatment options including high‐dose daptomycin in combination with an antistaphylococcal β‐lactam, ceftaroline, trimethoprim‐sulfamethoxazole (TMP‐SMX) or fosfomycin; ceftaroline alone or in combination with vancomycin or TMP‐SMX; linezolid alone or in combination with a carbapenem, or telavancin. What is new and conclusion Given the heterogeneity of the data, a preferred regimen has not emerged. Prescribers must take into consideration recent exposure, source control, and available synergy and clinical data. Further comparative trials are needed to establish a preferred regimen and the creation of a universal treatment algorithm.Keywords
Funding Information
- ALK Abello
This publication has 96 references indexed in Scilit:
- A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated NephrotoxicityAntimicrobial Agents and Chemotherapy, 2017
- Antibiotic resistance in Staphylococcus aureus. Current status and future prospectsFEMS Microbiology Reviews, 2017
- When sepsis persists: a review of MRSA bacteraemia salvage therapyJournal of Antimicrobial Chemotherapy, 2015
- Daptomycin in Combination With Other Antibiotics for the Treatment of Complicated Methicillin-Resistant Staphylococcus aureus BacteremiaClinical Therapeutics, 2014
- Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant Staphylococcus aureus bacteremiaDiagnostic Microbiology and Infectious Disease, 2010
- Risk factors for mortality in patients with persistent methicillin-resistant Staphylococcus aureus bacteraemia in a tertiary care hospital in TaiwanJournal of Antimicrobial Chemotherapy, 2010
- Vancomycin In Vitro Bactericidal Activity and Its Relationship to Efficacy in Clearance of Methicillin-Resistant Staphylococcus aureus BacteremiaAntimicrobial Agents and Chemotherapy, 2007
- Persistent Bacteremia Due to Methicillin‐ResistantStaphylococcus aureusInfection Is Associated withagrDysfunction and Low‐Level In Vitro Resistance to Thrombin‐Induced Platelet Microbicidal ProteinThe Journal of Infectious Diseases, 2004
- Clinical Identifiers of Complicated Staphylococcus aureus BacteremiaArchives of internal medicine (1960), 2003
- Comparison of Mortality Associated with Methicillin‐Resistant and Methicillin‐SusceptibleStaphylococcus aureusBacteremia: A Meta‐analysisClinical Infectious Diseases, 2003